


NEUROPROTECTIVE AND NEURORESTORATIVE THERAPEUTIC TECHNOLOGY PLATFORM



Achievements

- Genecode is the first to identify GFR α /RET receptor agonists that are:
 - Selective to relevant targets and enzymes
 - CNS available after peripheral administration
- **Proof-of-concept** demonstrated in vitro and in vivo:
 - In vitro DA neuron survival
 - In vivo restoration of rotation behavior acute and weeks after lesioning
 - In vivo restoration of lesioned dopaminergic neurons that carry TH and DAT
- Genecode's GDNF receptor agonists have the potential to restore dopamine neurotransmission and to render PD patients to a life without neurological symptoms

GENECODE PLATFORM TECHNOLOGIES PATENTS:

US Patent No.: US 8,901, 129 B2, Date of Patent Dec.2, 2014, European Patent No EP2509953, March 30, 2016

"METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS"

The diseases, targeted by this GENECODE Patent protected inventions are listed in the background information of the Patent, section (0014):

The disorders targeted by the present invention include Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson's disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, and other conditions involving degeneration or dysfunction of cells expressing GFR α /RET.

PARTNERING OPPORTUNITIES

Looking for development partners!
Contact person:
Mehis Pilv
mehis.pilv@gmail.com

GENECODE LTD, WTC Tallinn
Ahtri street 8, 10151, Tallinn
ESTONIA
www.genecode.com